Management of squamous blepharitis with manjisthadi ghan vati and pilla shukra nashak varti

A CLINICAL STUDY ON PRAKLINNAVARTMA (SQUAMOUS BLEPHARITIS) AND ITS MANAGEMENT WITH MANJISHTHADI GHANA TABLET AND PILLA SHUKRA NASHAKA VARTI - Squamous Blepharitis

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2016/12/007515

Enrollment

Registered

2016-12-01

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- patients diagnosed as squamous blepharitis

Interventions

Intervention1: Manjisthadi Ghana Tablet: 2 Manjisthadi Ghana Tablet of 500 mg each orally 3 times per day for one month Control Intervention1: Manjisthadi Ghana Tablet and Pilla Shukra Nashak Varti

Eligibility

Inclusion criteria

Inclusion criteria: The patients presenting with signs and symptoms of Squamous Blepharitis will be included in the study irrespective of sex, religion and occupation

Exclusion criteria

Exclusion criteria: Patients aged below 18 years and above 60 years Patients having diseases like Corneal Ulcer Ectropion Entropion Trichiasis Dacryocystitis Dry Eye Lagophthalmous Acute chronic infective conjunctivitis will be excluded from the study Patients suffering from specific eyelid disorders like Tumor Carcinoma or systemic diseases like Diabetes and Bleeding disorders will be excluded from the study

Design outcomes

Primary

Measure	Time frame
Improvement in signs lid edema congestion ulcer scaling and symptoms Nistoda Kandu heaviness in lidsTimepoint: Improvement in signs lid edema congestion ulcer scaling and symptoms Nistoda Kandu heaviness in lids afer 1 month	—

Secondary

Measure	Time frame
nillTimepoint: nill	—

Countries

India

Contacts

Public ContactDr Vijay Rathod

INSTITUTE FOR POST GRADUATION TEACHING AND RESEARCH IN AYURVEDA

drvijayrrathod@gmail.com8000425276

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026